Generation Investment Management Llp Has Increased By $43.32 Million Its Nike (NKE) Position; Eleven Biotherapeutics (EBIO) Sellers Decreased By 5.89% Their Shorts

October 6, 2017 - By Michael Collier

Generation Investment Management Llp increased Nike Inc (NKE) stake by 17.6% reported in 2017Q2 SEC filing. Generation Investment Management Llp acquired 746,942 shares as Nike Inc (NKE)’s stock declined 8.78%. The Generation Investment Management Llp holds 4.99 million shares with $294.51M value, up from 4.24 million last quarter. Nike Inc now has $85.73B valuation. The stock rose 0.10% or $0.05 reaching $52.23 per share. About 2.23M shares traded. Nike Inc (NYSE:NKE) has declined 9.24% since October 6, 2016 and is downtrending. It has underperformed by 25.94% the S&P500.

Eleven Biotherapeutics Incorporated (NASDAQ:EBIO) had a decrease of 5.89% in short interest. EBIO’s SI was 1.41 million shares in October as released by FINRA. Its down 5.89% from 1.50 million shares previously. With 221,800 avg volume, 6 days are for Eleven Biotherapeutics Incorporated (NASDAQ:EBIO)’s short sellers to cover EBIO’s short positions. The SI to Eleven Biotherapeutics Incorporated’s float is 16.22%. It is 0.00% or $0 reaching $1.51 per share. It is down 30.97% since October 6, 2016 and is uptrending. It has outperformed by 14.27% the S&P500.

Generation Investment Management Llp decreased Alphabet Inc stake by 348,049 shares to 268,923 valued at $244.38 million in 2017Q2. It also reduced Microsoft Corp (NASDAQ:MSFT) stake by 7.24 million shares and now owns 7.71M shares. Deere & Co (NYSE:DE) was reduced too.

Investors sentiment decreased to 1 in 2017 Q2. Its down 0.07, from 1.07 in 2017Q1. It fall, as 82 investors sold NKE shares while 439 reduced holdings. 110 funds opened positions while 410 raised stakes. 994.42 million shares or 3.48% less from 1.03 billion shares in 2017Q1 were reported. Paragon Lc owns 216,271 shares. Blair William And Company Il invested in 275,627 shares or 0.12% of the stock. Teachers Retirement Of The State Of Kentucky stated it has 592,044 shares or 0.44% of all its holdings. Private Asset Mgmt reported 9,108 shares. Estabrook holds 0% or 52,102 shares. Bancorporation Of Ny Mellon Corp reported 28.71M shares. 498,487 are held by Raymond James &. Bridgecreek Mngmt Limited Liability Company owns 116,265 shares for 1.83% of their portfolio. Ifc Hldg Fl stated it has 0.13% in Nike Inc (NYSE:NKE). Voya Invest Mngmt Limited Liability holds 0.09% or 715,426 shares in its portfolio. Smith Moore And Company accumulated 0.09% or 4,722 shares. At Commercial Bank has invested 0.03% of its portfolio in Nike Inc (NYSE:NKE). Gofen & Glossberg Ltd Llc Il has 0.78% invested in Nike Inc (NYSE:NKE) for 349,526 shares. Hamilton Point Inv Advisors Lc reported 47,786 shares. Professionals invested 0% in Nike Inc (NYSE:NKE).

Since June 1, 2017, it had 0 insider buys, and 1 insider sale for $3.66 million activity. 69,300 shares valued at $3.66M were sold by PARKER MARK G on Thursday, June 1.

Among 44 analysts covering Nike Inc. (NYSE:NKE), 25 have Buy rating, 2 Sell and 17 Hold. Therefore 57% are positive. Nike Inc. had 187 analyst reports since July 29, 2015 according to SRatingsIntel. Canaccord Genuity maintained the shares of NKE in report on Wednesday, September 28 with “Hold” rating. The firm has “Buy” rating by Goldman Sachs given on Wednesday, December 2. Telsey Advisory Group maintained Nike Inc (NYSE:NKE) on Tuesday, September 22 with “Outperform” rating. As per Tuesday, December 6, the company rating was downgraded by Cowen & Co. As per Wednesday, June 29, the company rating was maintained by Piper Jaffray. The firm earned “Buy” rating on Friday, June 30 by Jefferies. The rating was maintained by Cowen & Co with “Market Perform” on Thursday, March 23. The firm has “Buy” rating by Jefferies given on Thursday, December 17. The stock of Nike Inc (NYSE:NKE) earned “Equal-Weight” rating by Morgan Stanley on Wednesday, September 28. The stock of Nike Inc (NYSE:NKE) has “Buy” rating given on Wednesday, September 28 by Goldman Sachs.

Among 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Eleven Biotherapeutics had 4 analyst reports since August 15, 2015 according to SRatingsIntel. The rating was downgraded by Leerink Swann to “Market Perform” on Tuesday, January 19. The firm has “Neutral” rating by Citigroup given on Wednesday, March 16. The firm earned “Neutral” rating on Tuesday, January 19 by Citigroup. Leerink Swann maintained Eleven Biotherapeutics Inc (NASDAQ:EBIO) rating on Saturday, August 15. Leerink Swann has “Outperform” rating and $8.35 target.

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The company has market cap of $37.30 million. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. It has a 6.8 P/E ratio. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema and uveitis.